In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 records · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Elamipretide (SS-31) | ||
|---|---|---|---|
| Identity | |||
| Kind | Small molecule | Synthetic analog | |
| Area | Longevity and mitochondria | Longevity and mitochondria | |
| Evidence | |||
| Amount of evidence | 42 | 1,784 | |
| Evidence level | Results from animal studies only | Has results from studies in people | |
| Safety | |||
| Safety results | 1 (0 in people) | 35 (29 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | None registered | 30 · 3 active | |
Shared outcomes
From the regulatory data of each peptide.
Preclinical research only. No clinical trial phase found. The FDA, the EMA and the other sources we use show no approval (as of 13 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | SLU-PP-332 | Elamipretide (SS-31) |
|---|---|---|
| Mitochondrial functionMusculoskeletal | 624 | 4795258 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Forzinity says: “To improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg” No central EU authorisation (EMA).
| Heart functionCardiovascular | 33 | 120208614 |
|---|
| Inflammation markersKidney and urinary | 22 | 17312548 |
|---|
| Kidney functionKidney and urinary | 22 | 130611410 |
|---|
| Exercise and physical functionMusculoskeletal | 44 | 6220357 |
|---|
| Adverse eventsWhole body | 11 | 292621 |
|---|
| Receptor activity and mechanismPharmacology | 1138 | 883850 |
|---|
| Cell viability and deathMusculoskeletal | 11 | 561937 |
|---|
| Muscle injury and repairMusculoskeletal | 11 | 48444 |
|---|
| Aging markersMusculoskeletal | 11 | 362214 |
|---|
| PharmacokineticsPharmacology | 11 | 8233 |
|---|
| MortalityCardiovascular | 11 | 1019 |
|---|
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | SLU-PP-332 | Elamipretide (SS-31) |
|---|---|---|
| Exercise and physical functionMusculoskeletalCompared as: difference from placebo, in m | No randomized trial result 4 results from other study designs. | −3.2 m 6MWT least squares mean difference Dose studied: 40 mg/d24 weeksn = 2182023 |
| Kidney functionKidney and urinaryCompared as: value in the arm that got the peptide, in % | No randomized trial result 2 results from other study designs. | −6% Change in fractional hypoxia Placebo: 47% Dose studied: 0.05 mg/kg per hourbefore and during PTRAn = 142017 |
| Adverse eventsEyeCompared as: value in the arm that got the peptide, in % | No randomized trial result 1 result from other study designs. | 86% Adverse event rate Placebo: 71% Dose studied: 40 mg daily48 weeksn = 1762025 |
No randomized trial result
4 results from other study designs.
−3.2 m
6MWT least squares mean difference
Dose studied: 40 mg/d24 weeksn = 2182023
No randomized trial result
2 results from other study designs.
−6%
Change in fractional hypoxia
Placebo: 47%
Dose studied: 0.05 mg/kg per hourbefore and during PTRAn = 142017
No randomized trial result
1 result from other study designs.
86%
Adverse event rate
Placebo: 71%
Dose studied: 40 mg daily48 weeksn = 1762025
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
No registered trial that tests SLU-PP-332 found in ClinicalTrials.gov.
Top 3 of 30 trials, ranked by phase, then posted results and enrollment: 1 ongoing · 1 completed · 1 stopped early · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)
Stealth BioTherapeutics Inc.218 participants9 Oct 2017 to 10 Feb 2020
Primary Mitochondrial Myopathy
Stealth BioTherapeutics Inc.12 participants5 Jul 2017 to 11 Oct 2021
Barth Syndrome
Stealth BioTherapeutics Inc.313 participants30 May 2024 to est. Sept 2027
Age Related Macular Degeneration (ARMD)